Investigating a new RNA that affects immune response in aggressive breast cancer.
The long non-coding RNA LINC01133 as a novel determinant of immune evasion in triple-negative breast cancer
This study is looking at a type of breast cancer called triple-negative breast cancer, which often affects younger women of African and Latino backgrounds, to see how a specific molecule called LINC01133 might be making the cancer grow and resist treatment, with the goal of finding new ways to help improve care for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Boston Health Care System NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11003963 on NIH RePORTER |
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a particularly aggressive form of cancer that primarily affects younger women of African and Latino descent. The study aims to understand the role of a specific long non-coding RNA, LINC01133, which has been found to promote cancer growth and resistance to treatment. By analyzing tumor cells and their interactions with the immune system, the researchers hope to identify new therapeutic targets that could improve treatment outcomes for patients. The approach includes using anti-sense oligonucleotides to inhibit LINC01133 and assess its impact on cancer cell growth and immune response.
Who could benefit from this research
Good fit: Ideal candidates for this research are younger women of African and Latino descent diagnosed with triple-negative breast cancer.
Not a fit: Patients with other types of breast cancer or those who do not have triple-negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the immune response against triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting long non-coding RNAs for cancer treatment, suggesting potential success for this novel approach.
Where this research is happening
Boston, United States
- VA Boston Health Care System — Boston, United States (Active)
Researchers
- Principal investigator: Karnoub, Antoine Elias — VA Boston Health Care System
- Study coordinator: Karnoub, Antoine Elias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.